MGUS 进展为 MM 或相关疾病的风险约为每年 1%;血清单克隆蛋白的初始浓度是 20 年疾病进展的重要预测因素。[22]Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Clin Lymphoma Myeloma. 2005 Sep;6(2):102-14.http://www.ncbi.nlm.nih.gov/pubmed/16231848?tool=bestpractice.com[23]Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002 Feb 21;346(8):564-9.http://www.nejm.org/doi/10.1056/NEJMoa01133202http://www.ncbi.nlm.nih.gov/pubmed/11856795?tool=bestpractice.com
可影响 MGUS 转化的其他独立预后因素包括:1)免疫球蛋白A( IgA) 或 IgM 单克隆免疫球蛋白;2) 骨髓浆细胞增多>5%;3) Bence Jones 蛋白尿;4) 多克隆血清免疫球蛋白降低;5) 红细胞沉降率升高。[24]Bladé J. Clinical practice: monoclonal gammopathy of undetermined significance. N Engl J Med. 2006 Dec 28;355(26):2765-70.http://www.ncbi.nlm.nih.gov/pubmed/17192542?tool=bestpractice.com[25]Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002 Mar 15;20(6):1625-34.http://www.ncbi.nlm.nih.gov/pubmed/11896113?tool=bestpractice.com